Direct Meds Launches NAD+ Injection Therapy via Telehealth Subscription

Direct Meds, a US-based telehealth platform, now offers NAD+ injection therapy through a monthly subscription. The service connects patients with licensed providers and partner pharmacies for personalized treatment. However, availability excludes Mississippi and Louisiana due to local telehealth restrictions.

NAD+ is a coenzyme linked to cellular energy, DNA repair, and cognitive function. While over-the-counter supplements exist, injections provide different absorption and require medical oversight. Direct Meds ensures this by pairing patients with clinicians who assess suitability and prescribe dosages based on individual health needs.

The therapy is delivered through a monthly pricing plan covering provider consultations, pharmacy compounding, supplies, and shipping. Injections are administered subcutaneously and generally well-tolerated, though clinicians evaluate potential side effects on a case-by-case basis. Unlike unregulated 'research chemicals' sold online, these prescriptions follow strict medical protocols. Patients can contact Direct Meds by phone at (888) 696-7176 or via email at [email protected]. The service does not publicly list specific eligibility criteria, leaving final approval to the prescribing clinician.

Direct Meds expands access to NAD+ therapy across most US states, excluding those with telehealth limitations. The subscription model simplifies the process by bundling medical review, compounding, and delivery. Treatment remains tailored to individual health profiles, with clinicians determining safety and dosage.